 Brooklyn ImmunoTherapeutics LLC NYSE: BTX has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell MSC therapies using mRNA cell reprogramming and gene editing technologies licensed from Factor Bioscience. Under the terms of the LOI, the parties intend to sign a definitive agreement and work to close the acquisition by July 15. 